Five Prime Therapeutics Inc
COMBINATION THERAPY FOR CANCER
Last updated:
Abstract:
The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 to a subject in need thereof, for example, a cancer patient, in combination with a PD-1/PD-L1 antagonist, such as an anti-PD-1 antibody.
Status:
Application
Type:
Utility
Filling date:
7 Apr 2021
Issue date:
28 Oct 2021